MTERFD1 functions as an oncogene

Chaoxiong Zhang; Ning Wu; Fu Gao; Jiaqi Han; Yanyong Yang; Chuanfeng Zhou; Weimin Sun; Linfeng Xian; Ying Cheng; Bailong Li; Jianming Cai; Cong Liu

doi:10.18632/oncotarget.11140

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MTERFD1 functions as an oncogene

Chaoxiong Zhang, Ning Wu, Fu Gao, Jiaqi Han, Yanyong Yang, Chuanfeng Zhou, Weimin Sun, Linfeng Xian, Ying Cheng, Bailong Li, Jianming Cai and Cong Liu _

PDF | HTML | Supplementary Files | How to cite

DOI pending

Metrics: PDF 782 views | HTML 1965 views | ?

Abstract

Chaoxiong Zhang1,2,*, Ning Wu3,*, Fu Gao1,*, Jiaqi Han1, Yanyong Yang1, Chuanfeng Zhou1, Weimin Sun4, Linfeng Xian1, Ying Cheng1, Bailong Li1, Jianming Cai1, Cong Liu1

1Department of Radiation Medicine, Faculty of Naval Medicine, Second Military Medical University, Shanghai, 200433, PR China

2Institute of Military Medicine, Chengdu Military Region, Chengdu, 610021, China

3Department of Respiratory Medicine, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China

4Department of Immunology, Second Military Medical University, Shanghai, 200433, People’s Republic of China

*These authors contributed equally to this work

Correspondence to:

Jianming Cai, email: [email protected]

Cong Liu, email: [email protected]

Keywords: MTERFD1, cancers, prognosis, proliferation, survival

Received: October 02, 2015 Accepted: June 16, 2016 Published: August 09, 2016

ABSTRACT

MTERFD1, also named MTERF3 (mitochondrial transcription termination factor 3), regulates transcription of the mitochondrial genome. MTERFD1 is a mitochondrial protein that represses mammalian mitochondrial DNA initiation in vivo. In this study, we found that MTERFD1 gene amplification and high expression existed in many different types of cancer. Significantly, increased expression of MTERFD1 gene was correlated with lower overall survival rate in clinical. Overexpression of MTERFD1 gene promoted to tumor cell growth in vivo and in vitro and increased the percentage of cells in S phase. In conclusion, our data firstly indicated the MTERFD1 was an oncogene in many types of cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11140

Publication Alerts

Post-Publication Promotion

Research Papers:

MTERFD1 functions as an oncogene

Abstract